---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-24-007044"
form_type: "8-K"
ticker: null
cik: "0001098880"
company_name: "IntelGenx Technologies Corp."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:20:28.082036+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IntelGenx enters amended loan with ATAI; gets $1M now, $1M milestone loan; issues 4M warrants

## Summary
- New $1M First Tranche loan disbursed within 3 business days of March 11; $1M Second Tranche tied to successful VLS-01 OTF Ph1 readout.
- Conversion price for First Tranche set at US$0.185/share; Second Tranche uses greater of $0.185 or 5-day VWAP less max TSX discount.
- 4,000,000 warrants issued to ATAI at US$0.17/share, exercisable for 36 months; all securities unregistered under Section 4(a)(2).
- Existing loans amended and restated; Additional Term Loans mature Feb 1, 2026; interest at 14% per annum on new loans.
- Proceeds used for general corporate purposes, working capital, R&D.

## SEC filing metadata
- accession: 0001062993-24-007044
- form_type: 8-K
- cik: 0001098880
- company_name: IntelGenx Technologies Corp.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098880/000106299324007044/0001062993-24-007044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098880/000106299324007044/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-24-007044
- JSON: https://secwatch.observer/filing/0001062993-24-007044.json
- Plain text: https://secwatch.observer/filing/0001062993-24-007044.txt

## Key facts
- Debt Financings
  IntelGenx Technologies Corp. incurred term loan of US$1,000,000 with ATAI Life Sciences AG maturing February 1, 2026.
  - Instrument: term loan
  - Principal: US$1,000,000
  - Counterparty: ATAI Life Sciences AG
  - Maturity: February 1, 2026
  - Event: incurrence
  source text: (i) one (1) additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed within three (3) business days of the execution of the Loan Agreement (the " First Tranche Loan ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098880/000106299324007044/0001062993-24-007044-index.htm
- Debt Financings
  IntelGenx Technologies Corp. incurred term loan of US$1,000,000 with ATAI Life Sciences AG maturing February 1, 2026.
  - Instrument: term loan
  - Principal: US$1,000,000
  - Counterparty: ATAI Life Sciences AG
  - Maturity: February 1, 2026
  - Event: incurrence
  source text: (ii) one (1) additional term loan in the amount of US$1,000,000 to IntelGenx Corp., which loan is to be disbursed upon the achievement of a pre-defined milestone (the " Second Tranche Loan "
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098880/000106299324007044/0001062993-24-007044-index.htm
- Material Agreements
  IntelGenx Technologies Corp. amended Third Amended and Restated Loan Agreement with ATAI Life Sciences AG (effective 2024-03-11).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: ATAI Life Sciences AG
  - Effective: 2024-03-11
  source text: IntelGenx Technologies Corp. (the " Corporation ") entered into a Third Amended and Restated Loan Agreement dated March 11, 2024 (the " Loan Agreement ") with its wholly-owned subsidiary, IntelGenx Corp., and ATAI Life Sciences AG (" atai "), which amends and restates the Second Amended and Restated Loan Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098880/000106299324007044/0001062993-24-007044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.